Analysts See $-0.07 EPS for Atossa Genetics Inc. (ATOS); Last Week Home Capital Group Inc. (TSE:HCG) Analysts

February 10, 2018 - By Vivian Park

Among 5 analysts covering Home Capital Group Inc. (TSE:HCG), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Home Capital Group Inc. had 37 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Home Capital Group Inc. (TSE:HCG) earned “Sector Perform” rating by Scotia Capital on Friday, February 10. Raymond James maintained it with “Outperform” rating and $34 target in Friday, February 10 report. Scotia Capital initiated Home Capital Group Inc. (TSE:HCG) rating on Friday, June 30. Scotia Capital has “Sector Perform” rating and $18 target. RBC Capital Markets maintained the stock with “Sector Perform” rating in Thursday, November 3 report. The rating was maintained by Scotia Capital with “Sector Outperform” on Friday, July 31. On Monday, January 9 the stock rating was downgraded by RBC Capital Markets to “Underperform”. RBC Capital Markets maintained the shares of HCG in report on Thursday, November 5 with “Underperform” rating. Raymond James maintained the shares of HCG in report on Monday, May 1 with “Market Perform” rating. Raymond James maintained Home Capital Group Inc. (TSE:HCG) rating on Friday, October 28. Raymond James has “Outperform” rating and $35 target. The rating was upgraded by TD Securities on Friday, June 30 to “Hold”. See Home Capital Group Inc. (TSE:HCG) latest ratings:

13/09/2017 Broker: Laurentian Rating: Old Target: $17.00 New Target: $20.00 Target Up
25/08/2017 Broker: RBC Capital Markets Old Rating: Speculative Buy New Rating: Sector Perform Old Target: $14.00 New Target: $15.00 Downgrade

Analysts expect Atossa Genetics Inc. (NASDAQ:ATOS) to report $-0.07 EPS on March, 15.They anticipate $0.70 EPS change or 90.91% from last quarter’s $-0.77 EPS. After having $-0.17 EPS previously, Atossa Genetics Inc.’s analysts see -58.82% EPS growth. The stock decreased 3.88% or $0.0236 during the last trading session, reaching $0.5851. About 5.29 million shares traded or 15.24% up from the average. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since February 10, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $18.62 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

Home Capital Group Inc., through its subsidiary, Home Trust Company, provides deposits, mortgage lending, retail credit, and credit card issuing services in Canada. The company has market cap of $1.29 billion. It offers various deposit products, such as savings account demand products; and single-family residential and insured residential lending, as well as residential and non-residential commercial mortgage lending services. It has a 40 P/E ratio. The firm also provides credit card lending services, including Equityline Visa product that is secured by residential property; and cash-secured Visa products and unsecured Visa cards.

The stock decreased 0.25% or $0.04 during the last trading session, reaching $16.12. About 228,145 shares traded. Home Capital Group Inc. (TSE:HCG) has 0.00% since February 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: